Impoyz Patent Expiration

Impoyz is a drug owned by Primus Pharmaceuticals Inc. It is protected by 4 US drug patents filed from 2018 to 2020 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 11, 2035. Details of Impoyz's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10064875 Topical formulations comprising a steroid
Aug, 2030

(6 years from now)

Active
US10588914 Topical formulations comprising a steroid
Aug, 2030

(6 years from now)

Active
US9956231 Topical formulations comprising a steroid
Aug, 2030

(6 years from now)

Active
US9855334 Topical compositions comprising a corticosteroid
Mar, 2035

(10 years from now)

Active


FDA has granted several exclusivities to Impoyz. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Impoyz, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Impoyz.

Exclusivity Information

Impoyz holds 1 exclusivities. All of its exclusivities have expired in 2020. Details of Impoyz's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 28, 2020

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Impoyz is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Impoyz's family patents as well as insights into ongoing legal events on those patents.

Impoyz's family patents

Impoyz has patent protection in a total of 17 countries. It's US patent count contributes only to 48.8% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Impoyz.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Impoyz's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 11, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Impoyz Generics:

Clobetasol Propionate is the generic name for the brand Impoyz. 34 different companies have already filed for the generic of Impoyz, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Impoyz's generic

How can I launch a generic of Impoyz before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Impoyz's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Impoyz's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Impoyz -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.00025 06 Dec, 2019 1 11 Mar, 2035




About Impoyz

Impoyz is a drug owned by Primus Pharmaceuticals Inc. It is used for treating moderate to severe plaque psoriasis in patients 18 years of age or older. Impoyz uses Clobetasol Propionate as an active ingredient. Impoyz was launched by Primus Pharms in 2017.

Market Authorisation Date:

Impoyz was approved by FDA for market use on 28 November, 2017.

Active Ingredient:

Impoyz uses Clobetasol Propionate as the active ingredient. Check out other Drugs and Companies using Clobetasol Propionate ingredient

Treatment:

Impoyz is used for treating moderate to severe plaque psoriasis in patients 18 years of age or older.

Dosage:

Impoyz is available in cream form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.025% CREAM Prescription TOPICAL